.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Interchangeable Insulin Biosimilars: A Game Changer in Diabetes Management

The panel of experts in the management of diabetes review the role of insulin therapy and the place for biosimilars. They will review the approval process for biosimilars including the approval of the first interchangeable insulin biosimilar.

EP. 1: Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

EP. 2: Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Interchangeable Insulin Biosimilars: A Game Changer in Diabetes Management

EP. 1: Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

EP. 2: Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

EP. 3: Future Directions for the Use of Biosimilars in Diabetes

EP. 4: Addition of Pharmacists to Diabetes Management Teams Enhances Care

EP. 5: Role of Interchangeable Biosimilars in the Management of Diabetes

EP. 6: Results of INSTRIDE Studies for Diabetes Management

EP. 7: Basal Insulin Therapies for Diabetes Management